-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Mega Genomics Limited's (HKG:6667) Market Cap up HK$861m Last Week, Benefiting Both Private Companies Who Own 35% as Well as Insiders
Mega Genomics Limited's (HKG:6667) Market Cap up HK$861m Last Week, Benefiting Both Private Companies Who Own 35% as Well as Insiders
If you want to know who really controls Mega Genomics Limited (HKG:6667), then you'll have to look at the makeup of its share registry. The group holding the most number of shares in the company, around 35% to be precise, is private companies. In other words, the group stands to gain the most (or lose the most) from their investment into the company.
While private companies were the group that benefitted the most from last week's HK$861m market cap gain, insiders too had a 31% share in those profits.
In the chart below, we zoom in on the different ownership groups of Mega Genomics.
Check out our latest analysis for Mega Genomics
SEHK:6667 Ownership Breakdown November 21st 2022What Does The Lack Of Institutional Ownership Tell Us About Mega Genomics?
Institutional investors often avoid companies that are too small, too illiquid or too risky for their tastes. But it's unusual to see larger companies without any institutional investors.
There are multiple explanations for why institutions don't own a stock. The most common is that the company is too small relative to funds under management, so the institution does not bother to look closely at the company. On the other hand, it's always possible that professional investors are avoiding a company because they don't think it's the best place for their money. Mega Genomics' earnings and revenue track record (below) may not be compelling to institutional investors -- or they simply might not have looked at the business closely.
SEHK:6667 Earnings and Revenue Growth November 21st 2022We note that hedge funds don't have a meaningful investment in Mega Genomics. Meinian Onehealth Healthcare Holdings Co., Ltd. is currently the company's largest shareholder with 16% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 9.2% and 6.1%, of the shares outstanding, respectively.
We did some more digging and found that 8 of the top shareholders account for roughly 53% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat.
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There is some analyst coverage of the stock, but it could still become more well known, with time.
Insider Ownership Of Mega Genomics
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.
Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.
Our information suggests that insiders maintain a significant holding in Mega Genomics Limited. Insiders own HK$1.1b worth of shares in the HK$3.4b company. This may suggest that the founders still own a lot of shares. You can click here to see if they have been buying or selling.
General Public Ownership
The general public-- including retail investors -- own 16% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.
Private Company Ownership
It seems that Private Companies own 35%, of the Mega Genomics stock. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.
Public Company Ownership
We can see that public companies hold 18% of the Mega Genomics shares on issue. We can't be certain but it is quite possible this is a strategic stake. The businesses may be similar, or work together.
Next Steps:
It's always worth thinking about the different groups who own shares in a company. But to understand Mega Genomics better, we need to consider many other factors. For instance, we've identified 1 warning sign for Mega Genomics that you should be aware of.
Ultimately the future is most important. You can access this free report on analyst forecasts for the company.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
如果你想知道谁真正控制了兆丰基因有限公司(HKG:6667),那么你就得看看它的股票登记簿的构成。持有该公司股份最多的集团,准确地说约为35%,是私营公司。换句话说,该集团将从他们对公司的投资中获得最大(或损失最大)。
尽管民营企业是上周8.61亿港元市值增长的最大受益者,但内部人士也分享了31%的利润。
在下面的图表中,我们放大了兆丰基因的不同所有权集团。
查看我们对Mega Genology的最新分析
联交所:6667所有权分类2022年11月21日缺乏机构所有权告诉了我们关于兆丰基因的什么?
机构投资者往往会避开那些规模太小、流动性太差或风险太高的公司,这些公司对他们的口味来说太小了。但在没有任何机构投资者的情况下,看到较大的公司并不常见。
对于机构为何不持有股票,有多种解释。最常见的是,相对于管理下的资金,该公司规模太小,因此该机构不会费心密切关注该公司。另一方面,专业投资者总是可能会避开一家公司,因为他们认为这不是他们投资的最佳地方。美嘉基因的盈利和营收记录(见下文)对机构投资者来说可能并不具有说服力--或者他们可能只是没有密切关注这项业务。
联交所:6667盈利及收入增长2022年11月21日我们注意到,对冲基金并没有对兆丰基因进行有意义的投资。美年OneHealth Healthcare控股有限公司目前是该公司的最大股东,持有16%的流通股。与此同时,第二大和第三大股东分别持有9.2%和6.1%的流通股。
我们做了更多的挖掘,发现大股东中有8个约占登记册的53%,这意味着除了大股东外,还有一些小股东,从而在一定程度上平衡了彼此的利益。
虽然研究一家公司的机构所有权数据是有意义的,但研究分析师的情绪以了解风向也是有意义的。有一些分析师对该股的报道,但随着时间的推移,它仍可能变得更加广为人知。
兆丰基因的内部人所有权
尽管对内部人的准确定义可能是主观的,但几乎每个人都认为董事会成员是内部人。公司管理层对董事会负责,董事会应代表股东的利益。值得注意的是,有时最高层管理人员本身也是董事会成员。
内部人持股是积极的,当它标志着领导层像公司的真正所有者一样思考时。然而,高内部人持股也可以给公司内部的一个小团体带来巨大的权力。在某些情况下,这可能是负面的。
我们的信息显示,内部人士持有兆丰基因有限公司的大量股份。内部人士持有这家市值34亿港元的公司价值11亿港元的股票。这可能表明,创始人仍持有大量股份。您可以单击此处查看他们是在买入还是在卖出。
一般公有制
包括散户投资者在内的普通公众持有该公司16%的股份,因此不能轻易忽视。尽管这种规模的所有权可能不足以影响有利于他们的政策决定,但他们仍然可以对公司政策产生集体影响。
私营公司所有权
看起来,私营公司持有兆丰基因35%的股份。仅从这一事实很难得出任何结论,因此值得调查一下谁拥有这些私营公司。有时,内部人士或其他关联方通过一家独立的私人公司拥有上市公司的股份。
上市公司所有权
我们可以看到,上市公司持有兆丰基因已发行股票的18%。我们不能确定,但很有可能这是一个战略利益攸关方。这些业务可能是相似的,也可能是合作的。
接下来的步骤:
拥有一家公司股票的不同集团总是值得考虑的。但为了更好地理解兆丰基因组学,我们需要考虑许多其他因素。例如,我们已经确定兆丰基因组学的一个警告信号这一点你应该知道。
最终未来是最重要的。您可以访问此免费分析师对该公司的预测报告。
注:本文中的数字是使用过去12个月的数据计算的,指的是截至财务报表日期的最后一个月的12个月期间。这可能与全年的年度报告数字不一致。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧